Abstract
Improsulfan had the topical antitumor activity against Yoshida sarcoma cells, in comparison with cyclophosphamide. The mean survival time of rats bearing the tumor treated intraperitoneally with each optimal dose of improsulfan (10 mg/kg/day) or cyclophosphamide (5 mg/kg/day) from day 3 for 2 weeks was 32.2 or 31.7 days, respectively. In the sequential treatment of the two drugs, the mean survival time of the group administered with improsulfan for the first week and with cyclophosphamide for the second week was 46.3 days, which was the longest day among all of the groups tested. The therapeutic effect may be improved even by combinations of alkylating agents.
